PROOF Centre Biobank, Canada

Registration Status: Pending

Objective: To store all left over biospecimens, collected as part of PROOF Centre's biomarker research projects, for future research purposes. The biomarker research projects are focused on organ transplantation (liver, kidney, heart), heart failure, and chronic obstructive pulmonary disease (COPD). Additional research can be conducted on these samples to further knowledge on the disease and other chronic diseases related to the discovery of treatments, to validate drug targets, identify disease mechanisms, and help to discover and translate novel biomarkers into the clinic. This would be benefit researchers as it gives them access to samples already collected to do their research and it would benefit future patients with the disease or other chronic diseases. The biobank can provide the research community with resources needed to conduct future research.

Registered Biobank Name	PROOF Centre Biobank
Biobank Leader	Sara Assadian
Country	Canada
Email for biobank inquiries	sassadian@providencehealth.bc.ca
Principal Investigator	Dr. Bruce McManus
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).